Skip to main content
Donate

Industry

News

Oak Hill Bio to continue the development of rugonersen, an investigational ASO previously owned by Roche.

In June 2023, Roche announced they would not be moving forward with a clinical trial for rugonersen, an investigational ASO for AS, and would be looking for an external partner to take over the development. 

Oak Hill Bio enters into exclusive license agreement with Roche to obtain global rights for a Phase 3-Ready, Potential Best-in-Class Treatment for Individuals with Angelman Syndrome. 

Oak Hill Bio Ltd is a clinical-stage biotechnology company focused on acquiring and developing life-changing rare disease therapeutics.   

Read the press release

Read the community letter and FAQs

Related

IONIS REVEAL Phase 3 Clinical Trial Update
FAST announces the launch of two biotech companies to advance investigational gene-targeted therapies for Angelman syndrome
Ultragenyx Announces First Patient(s) Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
Ultragenyx Community Update October 2024

View All News

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.